This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           December 17, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store



GENETICS
 

Universal BRCA testing 'would break the bank'
Medscape (free login required)
The scientist who identified the BRCA1 gene has recommended that all women get tested for genetic mutations — but who will pay for it?
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




The new BRCA1/2 landscape
OncLive
As BRCA1/2 testing becomes more widely available in oncology practice, fresh questions about interpreting the results of these assays and a debate about which individuals should be screened for mutations have arisen.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


SGO NEWS


Late-breaking abstract submissions open until Feb. 5
SGO is accepting late-breaking abstract submissions for the Annual Meeting on Women’s Cancer® now through Feb. 5, 2015. This session will highlight data of the highest scientific impact that has become available since the original 2015 Annual Meeting abstract submission deadline on Sept. 17, 2014. Abstracts already submitted in response to the original Call for Abstracts for the 2015 Annual Meeting are not eligible for resubmission.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


CERVICAL CANCER


FDA approves new version of cervical cancer vaccine
The New York Times
The drug maker Merck received approval for an updated version of its Gardasil vaccine, which protects against the virus that causes most cases of cervical cancer. The Food and Drug Administration approved Gardasil 9, which protects against nine strains of the virus called HPV, or human papillomavirus, up from four strains covered by the original vaccine approved in 2006. The FDA said the updated Gardasil had the potential to prevent roughly 90 percent of cervical, vulvar, vaginal and anal cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISS AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


Potential new tool for cervical cancer detection and diagnosis
Phys.Org
A team of researchers from Central South University in China have demonstrated that a technique known as photoacoustic imaging, which is already under investigation for detecting skin or breast cancers and for monitoring therapy, also has the potential to be a new, faster, cheaper and non-invasive method to detect, diagnose and stage cervical cancer with high accuracy. Their work appears in a new paper in The Optical Society journal Biomedical Optics Express.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




OVARIAN CANCER


Researchers identify biological indicator of response to new ovarian cancer drug
OncologyNurseAdvisor
Researchers have found a way of identifying which patients with ovarian cancer are likely to respond well to the new anticancer drug rucaparib. These clinical trial results were presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain. Results of clinical trials have shown that women with tumors that are sensitive to platinum-based chemotherapy and who carry inherited mutations in the BRCA1/2 genes respond well to rucaparib. The new findings identified a biomarker that can predict which women without BRCA1/2 mutations will respond to the drug as well.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Mock 2
Dec. 3, 2014
Nov. 26, 2014
Nov. 19, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063